Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of iloprost in patients with septic shock-induced endotheliopathy-Protocol for the multicenter randomized, placebo-controlled, blinded, investigator-initiated trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. A marking of the cricothyroid membrane with extended neck returns to correct position after neck manipulation and repositioning

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association between transfusion of blood products and acute kidney injury following cardiac surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hypoxemia following hospital discharge after fast-track hip- and knee arthroplasty-a prospective observational study subanalysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Ketamine for rapid sequence intubation in adult trauma patients: A retrospective observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Metabolic Systems Analysis of Shock-Induced Endotheliopathy (SHINE) in Trauma: A New Research Paradigm

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lactate versus acetate buffered intravenous crystalloid solutions: a scoping review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Evaluating Non-Statistically Significant Results From Trials in Practice-Reply

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

BACKGROUND: In Europe 700.000 new cases of sepsis occur annually and more than 100.000 of these patients die due to multiorgan failure (MOF). We have identified shock-induced endotheliopathy (SHINE) to be associated with development of MOF and mortality. Furthermore, in patients with septic shock those with circulating levels of thrombomodulin (TM) above 10 ng/mL have twice the mortality (56% vs 28%) than those with levels below this level. Pilot studies indicate that infusion of iloprost (1 ng/kg/min) is associated with improved endothelial function in patients with septic shock.

MATERIAL AND METHODS: This is a multicenter, randomized, blinded, investigator-initiated, adaptive phase 2B trial in up to 384 patients with septic shock-induced endotheliopathy defined by TM > 10 ng/mL who are allocated 1:1 to 72 hours continuous infusion of iloprost 1 ng/kg/min or placebo (equal volume of saline). The primary outcome is the mean daily modified Sequential Organ Failure Assessment (SOFA) score in the ICU up to day 90. Secondary outcomes include 28- and 90-day all-cause mortality, days alive without vasopressor in the ICU within 90 days, days alive without mechanical ventilation in the ICU within 90 days, days alive without renal replacement therapy in the ICU within 90 days, numbers of serious adverse reactions, and the number of serious adverse events within the first 7 days.

DISCUSSION: This trial tests the safety and efficacy of iloprost vs placebo for 72 hours in patients with septic shock and SHINE. The outcome measures focus on the potential effect of the intervention to mitigate organ failure.

TRIAL REGISTRATION: COMBAT-SHINE trial-EudraCT no. 2019-001131-31-Clinicaltrials.gov: NCT04123444-Ethics Committee no. H-19018258.

Original languageEnglish
JournalActa Anaesthesiologica Scandinavica
Volume64
Issue number5
Pages (from-to)705-711
Number of pages7
ISSN0001-5172
DOIs
Publication statusPublished - May 2020

Bibliographical note

© 2020 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.

    Research areas

  • clinical trial, iloprost, septic shock-induced endotheliopathy, thrombomodulin

ID: 59030640